N6-methyladenosine-modified circPLPP4 sustains cisplatin resistance in ovarian cancer cells via PIK3R1 upregulation

Han Li,Run Lin,Yanna Zhang,Yanni Zhu,Shuting Huang,Jing Lan,Nian Lu,Chuanmiao Xie,Shanyang He,Weijing Zhang
DOI: https://doi.org/10.1186/s12943-023-01917-5
IF: 37.3
2024-01-08
Molecular Cancer
Abstract:Cisplatin (CDDP) is the first-line chemotherapeutic strategy to treat patients with ovarian cancer (OC). The development of CDDP resistance remains an unsurmountable obstacle in OC treatment and frequently induces tumor recurrence. Circular RNAs (circRNAs) are noncoding RNAs with important functions in cancer progression. Whether circRNAs function in CDDP resistance of OC is unclear.
oncology,biochemistry & molecular biology
What problem does this paper attempt to address?